Glypharma Overview

  • Founded
  • 2012

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Glypharma General Information

Description

Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The company's therapies include a novel proprietary Glucagon-Like Peptide-2 (GLP-2) analogue, enabling patients to get hematological malignancies for myelotoxic therapies.

Contact Information

Website
www.glypharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Therachon
Primary Office
  • 1188 Union
  • Suite 504
  • Montreal, Quebec H3B 0E5
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glypharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Oct-2018 0000 Completed Pre-Clinical Trials
1. Early Stage VC 05-Oct-2012 0000 0000 Completed Pre-Clinical Trials
To view Glypharma’s complete valuation and funding history, request access »

Glypharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The co
Biotechnology
Montreal, Canada
3 As of 2016
0000
000000&0 0000

000000

se cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

000000

co laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000000000000
Orlando, FL
0 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glypharma Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
000000 00000000000 Corporation Orlando, FL 0 000000000000
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 000.00
000000 00000000 Corporation Salt Lake City, UT 0000 00000 000000 - 000 00000
You’re viewing 5 of 63 competitors. Get the full list »

Glypharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glypharma Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Ferring International Center Corporation Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
To view Glypharma’s complete investors history, request access »

Ready to get started?

Request a free trial